GlycoNex Licenses SPD8 Biosimilar to Undisclosed Company for Osteoporosis Treatment
Taiwan-based GlycoNex, Inc. (TPEx: 4168) has announced a licensing agreement with an undisclosed company for...
Yiling Pharmaceutical Withdraws Clinical Filing for G201-Na in Assisted Reproduction
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced the withdrawal of its clinical filing...
Dizal’s Sunvozertinib Receives Priority Review from FDA for EGFR Exon 20 NSCLC
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...
Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta
Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro’s proprietary...
Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases
US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE:...
AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program
US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option...
Eyebright Medical’s Loong Crystal PR Receives NMPA Class III Medical Device Approval
China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050) has announced that it has received...
CSPC Pharmaceutical Group Receives NMPA Approvals for ADC SYS6045 and PDE4B Inhibitor SYH2059
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received separate clinical...
Kelun-Biotech’s Anti-HER2 ADC A166 Receives NMPA Review for Expanded Indication
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that another indication approval filing for...
PostEra Expands Partnership with Pfizer to Launch New ADC Collaboration
PostEra, a Boston-based biotech company powered by machine learning, has announced an expanded partnership with...
Merck KGaA Adopts Quris AI’s Bio-AI Platform for Drug Development Pipeline
Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced...
Hansoh and GSK’s HS-20093 Receives FDA Breakthrough Therapy Designation for Osteosarcoma
China-based Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692) and its UK partner GSK plc (LON:...
Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co. Launch Strategic Partnership for Linagliptin
On January 7, Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607,...
Merck KGaA Completes Acquisition of HUB Organoids, Expanding Cell Culture Portfolio
German major Merck KGaA (ETR: MRK) announced the completion of its acquisition of Holland-based HUB...
Amgen’s Imdylltra Gains Conditional Approval in UK for Extensive-Stage Small Cell Lung Cancer
US biotech company Amgen (NASDAQ: AMGN) has received conditional approval from the UK’s Medicines and...
Mabwell Bioscience Files for IPO on Hong Kong Stock Exchange, Expanding Biopharma Reach
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has officially filed for an initial public offering...
WuXi Biologics to Sell Irish Vaccine Assets to MSD for USD 500 Million
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) is poised to...
Junshi Biosciences’ Loqtorzi Gains Regular Approval for Melanoma Treatment in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its PD-1 inhibitor,...
Simcere Zaiming’s SIM0505 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced that it has...
NMPA Releases 88th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 88th batch of reference drugs for...